natgillin/translations-raw huggingface dataset:
Caution should be exercised in patients who are taking EXJADE in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm3 (50 x 109/l) (see section 4.5).
Nužan je oprez u bolesnika koji uzimaju EXJADE u kombinaciji s lijekovima koje imaju dokazani ulcerogeni potencijal, poput nesteroidnih protuupalnih lijekova, kortikosteroida ili oralnih bisfosfonata, u bolesnika koji primaju antikoagulanse, kao i u bolesnika s brojem trombocita ispod 50 000/mm3 (50 x 109/l) (vidjeti dio 4.5).
Caution should be exercised in patients with a history of pancreatitis.
Potreban je oprez pri liječenju bolesnika s pankreatitisom u anamnezi..
Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug--seeking behaviour have been reported).
Potreban je oprez kod primjene lijeka u bolesnika s anamnezom zlouporabe sredstava ovisnosti te takve bolesnike treba nadzirati kako bi se uočili simptomi pogrešne primjene, zlouporabe ili ovisnosti o pregabalinu (prijavljeni su slučajevi razvoja tolerancije, povećanja doze i kompulzivnog traženja lijeka).
Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have been reported).
Potreban je oprez kod primjene lijeka u bolesnika sa zlouporabom sredstava ovisnosti u anamnezi te takve bolesnike treba nadzirati kako bi se uočili simptomi pogrešne primjene, zlouporabe ili ovisnosti o pregabalinu (prijavljeni su slučajevi razvoja tolerancije, povećanja doze i kompulzivnog traženja lijeka).
Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
Mora se s oprezom postupati u bolesnika koji iz bilo kojeg razloga imaju snižene vrijednosti leukocita i/ili neutrofila, zatim u bolesnika koji primaju lijekove za koje se zna da mogu prouzročiti neutropeniju, u bolesnika s anamnezom depresije/toksičnosti koštane srži uzrokovane lijekovima te u onih u kojih je do depresije koštane srži došlo uslijed istodobno prisutne bolesti, terapije zračenjem ili kemoterapije, kao i u bolesnika s hipereozinofilnim stanjima ili s mijeloproliferativnom bolešću.
Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
Oprez je potreban u bolesnika s niskim brojem leukocita i/ili neutrofila iz bilo kojeg razloga, u bolesnika koji primaju lijekove za koje se zna da uzrokuju neutropeniju, u bolesnika s anamnezom depresije/toksičnosti koštane srži uzrokovane lijekovima, u bolesnika s depresijom koštane srži uzrokovane istodobno prisutnom bolešću, zračenjem ili kemoterapijom te u bolesnika s hipereozinofilnim stanjima ili mijeloproliferativnom bolesti.
Caution should be exercised in patients with moderate renal impairment.
Potreban je oprez u bolesnika s umjerenim oštećenjem bubrega.
Caution should be exercised in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilization, severely hypovolemic patients, patients with diseases which increase blood viscosity).
Treba biti oprezan u bolesnika s prethodnim faktorima rizika za trombotske događaje (poput uznapredovale dobi, hipertenzije, dijabetesa mellitusa i anamneze vaskularnih bolesti ili trombotskih epizoda, bolesnika sa stečenim ili naslijeđenim trombofilijskim poremećajima, bolesnici s produljenim razdobljima imobilizacije, bolesnika s jakim hipovolemijskim šokom, bolesnika s bolestima koje povećavaju viskoznost krvi).
Caution should be exercised in patients with previous autoimmune conditions other than MS, although available data suggests there is no worsening of pre-existing autoimmune conditions after alemtuzumab treatment.
Potreban je oprez u bolesnika s prethodnim autoimunim stanjim,a osim multiple skleroze, premda dostupni podaci upućuju da nakon liječenja alemtuzumabom nije došlo do pogoršanja već postojećih autoimunih stanja.
Caution should be exercised in patients with risk factors for QT prolongation , including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities.
Potreban je oprez u bolesnika s faktorima rizika za produženje QT-a, uključujući bolesnike s osobnom ili obiteljskom anamnezom produženja QT-a, kongestivnim zatajenjem srca, bradiaritmijama i poremećajem elektrolita.
Caution should be exercised in patients with risk factors for QT prolongation, including patients risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities.
Potreban je oprez u bolesnika s faktorima rizika za produženje QT-a, uključujući bolesnike koji u osobnoj ili obiteljskoj anamnezi imaju produženje QT-a, kongestivno zatajenje srca, bradiaritmije i poremećaje elektrolita.
Caution should be exercised in patients with risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities.
Potreban je oprez u bolesnika s faktorima rizika za produljenje QT-a, uključujući bolesnike koji u osobnoj ili obiteljskoj anamnezi imaju produljenje QT-a, kongestivno zatajenje srca, bradiaritmije i poremećaje elektrolita.
Caution should be exercised in patients with severe renal impairment (see section 4.4).
U bolesnika s teškim oštećenjem bubrega potreban je oprez (vidjeti dio 4.4).
Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, and patients with diseases which increase blood viscosity).
Potrebna je pozornost u propisivanju i primjeni i.v. infuzije Ig u pretilih bolesnika i u bolesnika s postojećim čimbenicima rizika za trombotične događaje (poodmakla životna dob, visoki tlak, šećerna bolest, anamneza krvožilnih bolesti ili trombotičnih epizoda, bolesnici sa stečenim ili naslijeđenim trombofilnim poremećajima, bolesnici s duljim razdobljima imobilizacije, bolesnici s teškom hipovolemijom te bolesnici s bolestima koje povećavaju viskoznost krvi).
Caution should be exercised in prescribing and infusion of IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypertension, use of estrogens, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, hypercoagulable disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity, patients with indwelling vascular catheters and patients with high dose and rapid infusion).
Oprez je nužan pri propisivanju i infuziji i.v. imunoglobulina pretilim bolesnicima i bolesnicima s postojećim faktorima rizika za trombotičke događaje (kao što su ateroskleroza u anamnezi, multipli kardiovaskularni faktori rizika, starija dob, smanjen minutni volumen, hipertenzija, uzimanje estrogena, dijabetes i bolesti krvnih žila ili trombotičke epizode u anamnezi, bolesnicima sa stečenim ili nasljednim trombofilijskim poremećajima, hiperkoagulacijskim poremećajima, bolesnicima s produljenim razdobljima imobilizacije, bolesnicima s teškom hipovolemijom te bolesnicima s bolestima koje povećavaju viskoznost krvi, bolesnicima s trajnim vaskularnim kateterima i bolesnicima koji primaju visoku dozu infuzije velikom brzinom).
Caution should be exercised in the administration of Dacogen to patients with hepatic impairment and patients should be monitored closely (see sections 4.2 and 5.2).
Kad se Dacogen primjenjuje u bolesnika s oštećenom funkcijom jetre potrebno je postupati s oprezom, a bolesnike pažljivo nadzirati (vidjeti dijelove 4.2 i 5.2).
Caution should be exercised in the administration of Dacogen to patients with severe renal impairment (Creatinine Clearance [CrCl] < 30 ml/min) and these patients should be monitored closely (see section 4.2).
Kad se Dacogen primjenjuje u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina [CrCl] < 30 ml/min) potrebno je postupati s oprezom, a bolesnike pažljivo nadzirati (vidjeti dio 4.2).
Caution should be exercised in the course of treatment with methylthioninium chloride as this may exacerbate Heinz body formation and haemolytic anaemia.
Nužan je oprez tijekom liječenja metiltioninijev kloridom jer može potaknuti formiranje Heinzovih tijela i hemolitičke anemije.
Caution should be exercised in the handling and preparation of Myocet.
Prilikom pripreme i rukovanja Myocetom treba biti oprezan.
Caution should be exercised in the treatment of patients with renal impairment and the dose should be adjusted according to creatinine clearance (CLCR) as follows:
Potreban je oprez u liječenju bolesnika s oštećenjima bubrega i dozu treba prilagoditi prema klirensu kreatinina (CLCR) kako slijedi:
Caution should be exercised in these patients.
Potreban je oprez u ovih bolesnika.
Caution should be exercised when
Nužan je oprez pri istovremenoj
Caution should be exercised when administering Bosulif concomitantly with proton pump inhibitors (PPIs).
Nužan je oprez kada se Bosulif primjenjuje istodobno s inhibitorima protonske pumpe (IPP).
Caution should be exercised when administering Enbrel in patients previously infected with HBV.
B. Nužan je oprez u slučaju davanja Enbrela bolesnicima koji su prethodno bili zaraženi HBV-om.
Caution should be exercised when administering such products (e.g. midazolam, erythromycin, nifedipine), especially for those with a narrow therapeutic index (e.g. alfentanil, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus).
Potreban je oprez kada se primjenjuju takvi lijekovi (npr. midazolam, eritromicin, nifedipin), naročito oni s uskim terapijskim indeksom (npr. alfentanil, dihidroergotamin, ergotamin, fentanil, pimozid, kinidin, sirolimus, takrolimus).
Caution should be exercised when administering Zydelig in patients with active hepatitis.
Potreban je oprez pri primjeni Zydeliga u pacijenata s kroničnim aktivnim hepatitisom.
Caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as an increased risk of hypoglycaemia has been observed with this triple therapy (see section 4.4).
Nužan je oprez kada se alogliptin primjenjuje u kombinaciji s metforminom i tiazolidindionom jer je primjećen povećani rizik od hipoglikemije s ovom trojnom terapijom (vidjeti dio 4.4).
Caution should be exercised when ataluren is co-administered with medicinal products that are inducers of UGT1A9 (e.g. mycophenolate mofetil), or inhibitors of BCRP (e.g. cyclosporine).
Poseban je oprez potreban kada se ataluren primjenjuje istovremeno s lijekovima koji su induktori UGT1A9 (primjerice mikofenolat mofetil) ili inhibitori BCRP-a (primjerice ciklosporin).
Caution should be exercised when ataluren is co-administered with medicinal products that are substrates of UGT1A9, OAT1, OAT3, or OATP1B3 because of the risk of increase concentration of these medicinal products (eg, oseltamivir, acyclovir, ciprofloxacin, captopril, furosemide, bumetanide, valsartan, pravastatin, rosuvastatin, atorvastatin, pitavastatin).
Potreban je oprez ako se ataluren primjenjuje istovremeno s lijekovima koji su supstrati UGT1A9, OAT1, OAT3 ili OATP1B3 zbog rizika od povećanja koncentracije ovih lijekova (primjerice oseltamivira, aciklovira, ciprofloksacina, kaptoprila, furosemida, bumetanida, valsartana, pravastatina, rosuvastatina, atorvastatina, pitavastatina).
Caution should be exercised when ataluren is co-administered with medicinal products that are substrates or inducers of UGT1A9, inhibitors of BCRP, or substrates of OAT1, OAT3, or OATP1B3 (see section 4.5).
Potreban je oprez u slučaju uzimanja atalurena istovremeno s lijekovima koji su supstrati ili induktori UGT1A9, inhibitori BCRP ili supstrati OAT1, OAT3 ili OATP1B3 (vidjeti dio 4.5.).
Caution should be exercised when AVONEX is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. some classes of antiepileptics and antidepressants.
S osobitom pozornošću treba davati AVONEX u kombinaciji s lijekovima koji imaju uzak terapijski indeks i čije je uklanjanje jako ovisno o jetrenom enzimskom P450 sustavu, primjerice neke skupine antiepileptika i antidepresiva.
Caution should be exercised when AVONEX is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. some classes of antiepileptics and antidepressants.
S osobitom pozornošću treba davati AVONEX u kombinaciji s lijekovima koji imaju uzak terapijski indeks i čije je uklanjanje jako ovisno o jetrenom enzimskom P450 sustavu, primjerice neke skupine antiepileptika iantidepresiva.
Caution should be exercised when Bortezomib Hospira is combined with CYP3A4- or CYP2C19 substrates (see section 4.5).
Potreban je oprez kad se Bortezomib Hospira kombinira sa supstratima enzima CYP3A4 ili CYP2C19 (vidjeti dio 4.5).
Caution should be exercised when co-administering Dynastat with warfarin and other oral anticoagulants (see section 4.5).
Potreban je oprez kad se Dynastat primjenjuje istodobno s varfarinom i drugim oralnim antikoagulansima (vidjeti dio 4.5).
Caution should be exercised when co-administering Genvoya with pitavastatin.
Istodobnu primjenu lijeka Genvoya i pitavastatina mora se provoditi s oprezom.
Caution should be exercised when co-administering Stribild and a hormonal contraceptive.
Istovremena primjena Stribilda i hormonske kontracepcije mora se provoditi s oprezom.
Caution should be exercised when co-administering Stribild with pitavastatin.
Istovremenu primjenu Stribilda i pitavastatina mora se provoditi s oprezom.
Caution should be exercised when co-administering Tybost with pitavastatin.
Istovremenu primjenu lijeka Tybost i pitavastatina mora se provoditi s oprezom.
Caution should be exercised when considering belimumab therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy.
Potreban je oprez pri razmatranju terapije belimumabom u bolesnika s anamnezom maligne bolesti ili pri procjeni nastavka liječenja u bolesnika koji su razvili maligni tumor.
Caution should be exercised when considering the administration of Luminity to these patients.
Potreban je oprez kada se razmatra primjena Luminityja tim bolesnicima.
Caution should be exercised when considering the use of Cosentyx in patients with a chronic infection or a history of recurrent infection.
Potreban je oprez kada se razmatra primjena Cosentyxa u bolesnika s kroničnom infekcijom ili rekurentnom infekcijom u anamnezi.
Caution should be exercised when considering the use of Inflectra in patients with chronic infection or a history of recurrent infections, including concomitant immunosuppressive therapy.
Potreban je oprez kad se razmatra mogućnost primjene lijeka Inflectra u bolesnika s kroničnim ili rekurirajućim infekcijama, uključujući one koji istodobno primaju imunosupresive.
Caution should be exercised when considering the use of Remsima in patients with chronic infection or a history of recurrent infections, including concomitant immunosuppressive therapy.
Potreban je oprez kad se razmatra mogućnost primjene lijeka Remsima u bolesnika s kroničnim ili rekurirajućim infekcijama, uključujući one koji istodobno primaju imunosupresive.
Caution should be exercised when considering the use of Simponi in patients with a chronic infection or a history of recurrent infection.
Potreban je oprez kad se razmatra mogućnost primjene lijeka Simponi u bolesnika s kroničnim ili rekurentnim infekcijama u anamnezi.
Caution should be exercised when considering the use of sugammadex in patients receiving therapeutic anticoagulation for a pre-existing or co- morbid condition.
Oprez je potreban kada se razmatra primjena sugamadeksa u bolesnika koji se liječe antikoagulansima zbog već postojećih ili popratnih bolesti.
Caution should be exercised when dosing lapatinib concurrently with medicinal products with narrow therapeutic windows that are substrates of Pgp, and a reduction in the dose of the Pgp substrate should be considered.
Potreban je oprez kada se lapatinib primjenjuje istodobno s lijekovima uske terapijske širine koji su supstrati za Pgp, a smanjivanje doze Pgp supstrata potrebno je uzeti u obzir.
Caution should be exercised when emtricitabine is co-administered with medicinal products that are eliminated by active tubular secretion as such co-administration may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product, due to competition for this elimination pathway (see section 4.5).
Nužno je oprezno postupati pri istovremenoj primjeni emtricitabina i lijekova koji se eliminiraju aktivnom tubularnom sekrecijom jer istovremena primjena može povećati serumsku koncentraciju emtricitabina ili istovremeno primijenjenog lijeka, zbog natjecanja za taj put eliminacije (vidjeti dio 4.5).
Caution should be exercised when initiating treatment with Xadago in patients with moderate hepatic impairment.
Potreban je oprez prilikom početka liječenja lijekom Xadago u bolesnika s umjerenim oštećenjem jetre.
Caution should be exercised when Invirase/ritonavir and digoxin are co- administered.
Potreban je oprez kad se lijekovi Invirase/ritonavir primjenjuju istodobno s digoksinom.
Caution should be exercised when lurasidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, hypokalaemia, and in concomitant use with other medicinal products thought to prolong the QT interval.
Potreban je povećani oprez kad se lurasidon propisuje bolesnicima koji boluju od kardiovaskularnih bolesti ili s obiteljskom anamnezom produženog QT intervala, hipokalemijom i u istovremenoj primjeni s drugim lijekovima za koje se smatra da produžuju QT interval.
Caution should be exercised when lurasidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, hypokalaemia, and in concomitant use with other medicinal products thought to prolong the QT interval.
Potreban je povećani oprez kad se lurasidon propisuje bolesnicima koji boluju odkardiovaskularnih bolesti ili s obiteljskom anamnezom produženog QT intervala, hipokalemijom i u istovremenoj primjeni s drugim lijekovima za koje se smatra da produžuju QT interval.
Caution should be exercised when macitentan is administered concomitantly with strong CYP3A4 inhibitors (see section 4.4).
Potreban je oprez prilikom primjene macitentana istovremeno s jakim inhibitorima CYP3A4 (vidjeti dio 4.4).
Caution should be exercised when patients receiving a beta blocker are administered a dihydropyridine.
Mora se biti oprezan kad bolesnici uzimaju beta-blokatore s dihidropiridinima.
Caution should be exercised when Plegridy is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. some classes of antiepileptics and antidepressants.
Plegridy treba davati s osobitom pozornošću u kombinaciji s lijekovima koji imaju uzak terapijski indeks i čiji je klirens vrlo ovisan o sustavu jetrenog P450 citokroma, primjerice s antiepilepticima i nekim skupinama antidepresiva.
Caution should be exercised when prescribing Cosentyx to patients with Crohn’s disease as exacerbations of Crohn’s disease, in some cases serious, were observed in clinical studies in both Cosentyx and placebo groups.
Potreban je oprez pri propisivanju Cosentyxa bolesnicima s Crohnovom bolešću, budući da su u kliničkim ispitivanjima uočene egzacerbacije Crohnove bolesti, u nekim slučajevima ozbiljne, kako u skupinama liječenim Cosentyxom tako i u onima koje su primale placebo.
Caution should be exercised when prescribing nevirapine to pregnant women (see section 4.4).
Stoga je nužan oprez u propisivanju Viramunea trudnicama (vidjet dio 4.4).
Caution should be exercised when prescribing nevirapine to pregnant women (see section 4.4).
Stoga je nužan oprez u propisivanju Viramunea trudnicama (vidjeti dio 4.4).
Caution should be exercised when prescribing nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol).
Analoge nukleozida treba propisivati s oprezom svim bolesnicima (posebno pretilim ženama) s hepatomegalijom, hepatitisom ili drugim poznatim faktorima rizika za razvoj bolesti jetre i steatozu jetre (uključujući određene lijekove i alkohol).
Caution should be exercised when prescribing nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease.
Nužan je oprez pri propisivanju nukleozidnih analoga bilo kojem bolesniku (posebno pretilim ženama) s hepatomegalijom, hepatitisom ili ostalim poznatim čimbenicima rizika za bolest jetre.
Caution should be exercised when prescribing Ranexa to patients:
Treba postupati s oprezom kod propisivanja Ranexe bolesnicima:
Caution should be exercised when prescribing Renvela to patients also taking these medicinal products.
Potreban je oprez pri propisivanju lijeka Renvela bolesnicima koji uzimaju navedene lijekove.
Caution should be exercised when prescribing Sevelamer carbonate Zentiva to patients also taking these medicinal products.
Potreban je oprez pri propisivanju lijeka Sevelamer carbonate Zentiva bolesnicima koji uzimaju navedene lijekove.
Caution should be exercised when prescribing tadalafil to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin) as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section 4.5).
Savjetuje se oprez kod propisivanja tadalafila bolesnicima koji uzimaju jake inhibitore CYP3A4 (ritonavir, sakvinavir, ketokonazol, itrakonazol i eritromicin) jer je kod kombinacije navedenih lijekova primijećena povećana izloženost tadalafilu (AUC) (vdjeti dio 4.5).
Caution should be exercised when prescribing tadalafil to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin) as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section 4.5).
Savjetuje se oprez kod propisivanja tadalafila bolesnicima koji uzimaju jake inhibitore CYP3A4 (ritonavir, sakvinavir, ketokonazol, itrakonazol i eritromicin) jer je kod kombinacije navedenih lijekova primijećena povećana izloženost tadalafilu (AUC) (vidjeti dio 4.5).